INTRODUCTION {#s1}
============

Cancer is a substantial public health burden, with an estimate of 14.1 million new cancer cases and 8.2 million cancer-related deaths occurred globally \[[@R1]\]. Although progress has been achieved in understanding the etiology of carcinogenesis, the definitive etiology still remains not yet fully elucidated. Mounting evidences have suggested that cancer is a multifactorial disease caused by genetic and environmental interactions \[[@R2]--[@R4]\].

Telomerase is an RNA-dependent DNA polymerase containing two essential components, catalytic subunit with the reverse transcriptase activity and an essential structural RNA component with a sequence complementary to the telomere sequence \[[@R5]\]. *TERT* gene is located on the short (p) arm of chromosome 5 at position 15.33 (5p15.33), and composes of 16 exons \[[@R6], [@R7]\]. *TERT* gene encodes the reverse transcriptase component of the telomerase, which is essential in maintaining the length of telomer \[[@R8]\]. In addition, telomerase is also responsible for chromosomal stability, and cellular immortality \[[@R9]\]. Telomeres might become shorter during mitosis due to incomplete replication of linear chromosomes by conventional DNA polymerases \[[@R10]\]. Normally, *TERT* mRNA is not expressed in most human somatic cells; however, aberrant expression of *TERT* mRNA and protein are associated with development of various cancers \[[@R11], [@R12]\].

More and more epidemiological studies were accessible regarding the association between the *TERT* rs2736098 polymorphism and cancer risk, yet conflicting conclusions remain. Besides, the latest meta-analysis was performed a year ago, which updated to March 2015. Nearly 10 new case-control studies with larger sample size were published since then. Thus, it is of great value to updated the meta-analysis regarding the association of interest. The current meta-analysis was the most comprehensive to date, which undoubtedly will shed some light on the current uncertain claims.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

A total of 144 potentially relevant publications were initially identified from the databases. After screening titles and abstracts, 106 publications were excluded because of their failure to reach inclusion criteria. The remaining 38 publications were further assessed through careful reading. We further excluded 8 publications based on the following reasons: 7 publications were meta-analyses \[[@R13]--[@R19]\], 1 was case only research \[[@R20]\]. 2 additional publications were further extracted by manually screening the references of the retrieval articles \[[@R21], [@R22]\]. As a result, 33 studies including 32 publications were used for investigation \[[@R13], [@R16], [@R21]--[@R50]\]. The general workflow of selecting the eligible studies was graphically shown in Figure [1](#F1){ref-type="fig"}.

![Flowchart of included studies](oncotarget-08-96433-g001){#F1}

In general, the current study contains 18685 cases and 23820 controls (Table [1](#T1){ref-type="table"}). Studies were conducted on several cancer types, including lung cancer, bladder cancer, breast cancer, colorectal cancer, cervical cancer, glioma, hepatocellular carcinoma (HCC), oral squamous cell carcinoma (OSCC), acute lymphoblastic leukemia (ALL), renal cell carcinoma (RCC), squamous cell carcinoma of head and neck (SCCHN), pancreatic cancer, esophageal carcinoma. In terms of ethnicities, 23 studies focused on Asians and 10 on Caucasians. Of these, there were 24 hospital based and 9 population based data sets. 18 studies were categorized as low quality and 15 were high quality. The controls' genotype frequencies in agreement with Hardy-Weinberg equilibrium (HWE) was observed in 27 studies, while not available in 6 studies.

###### Characteristics of studies included in the current meta-analysis

  Surname          Year   Cancer type   Country   Ethnicity   Control Source   Genotype method   Genotype quality   Case   Control   HWE   Score                                      
  ---------------- ------ ------------- --------- ----------- ---------------- ----------------- ------------------ ------ --------- ----- ------- ------ ------ ----- ------ ------- ----
  Savage           2007   Breast        Poland    Caucasian   PB               TaqMan            High               1171   699       97    1967    1313   811    141   2265   0.294   13
  Choi             2009   Lung          Korea     Asian       HB               PCR-RFLP          High               311    322       87    720     345    320    55    720    0.101   11
  Liu              2010   SCCHN         USA       Caucasian   HB               TaqMan            High               588    419       72    1079    576    461    78    1115   0.271   11
  Gago-Dominguez   2011   Bladder       USA       Caucasian   PB               TaqMan            High               217    189       43    449     278    210    43    531    0.706   12
  Gago-Dominguez   2011   Bladder       China     Asian       PB               TaqMan            High               178    236       85    499     203    270    54    527    0.009   12
  Ding             2011   HCC           China     Asian       HB               TaqMan            Low                500    563       210   1273    526    604    198   1328   0.255   9
  Chen             2011   Glioma        China     Asian       HB               MassARRAY         High               351    461       141   953     430    486    117   1033   0.246   11
  Liu              2011   SCCHN         USA       Caucasian   HB               TaqMan            Low                481    351       56    888     468    356    61    885    0.546   9
  Xu               2012   Gastric       China     Asian       HB               PCR-RFLP          High               116    130       51    297     119    137    50    306    0.322   10
  Hofer            2012   Colorectal    Austria   Caucasian   PB               TaqMan            High               86     45        6     137     963    623    119   1705   0.186   12
  Wang             2012   Cervical      China     Asian       PB               TaqMan            High               375    444       174   993     397    480    138   1015   0.710   12
  Li               2013   Lung          China     Asian       HB               TaqMan            High               173    207       88    468     227    250    67    544    0.886   10
  Ma               2013   Bladder       China     Asian       PB               MassARRAY         High               71     75        28    174     373    461    127   961    0.408   12
  Sheng            2013   ALL           China     Asian       PB               TaqMan            High               236    238       93    567     276    298    96    670    0.286   14
  Wu               2013   Lung          China     Asian       HB               TaqMan            Low                205    232       102   539     263    278    86    627    0.361   8
  Zhang            2013   HCC           China     Asian       HB               PCR-RFLP          Low                133    206       61    400     177    158    65    400    0.004   9
  Gao              2014   Lung          China     Asian       HB               MassARRAY         Low                122    145       42    309     137    143    28    308    0.104   7
  Hashemi          2014   Breast        Iran      Asian       PB               PCR-RFLP          Low                72     140       40    252     51     113    58    222    0.777   7
  Singh            2014   Bladder       India     Asian       HB               TaqMan            High               77     106       42    225     117    95     28    240    0.203   9
  Su               2014   HCC           China     Asian       HB               TaqMan            Low                75     97        29    201     111    76     23    210    0.077   8
  Yin              2014   Esophageal    China     Asian       HB               PCR               High               245    277       78    600     270    306    75    651    0.403   11
  Zhang            2014   Lung          China     Asian       HB               PCR               High               135    173       58    366     157    171    36    364    0.283   10
  Zhao             2014   Lung          China     Asian       HB               TaqMan            High               337    438       177   952     406    443    106   955    0.365   12
  Campa            2015   Pancreatic    Mixed     Caucasian   PB               TaqMan            Low                980    584       126   1690    1839   1307   251   3397   0.372   9
  Jannuzzi         2015   Colorectal    Turkey    Caucasian   HB               PCR-RFLP          Low                25     14        65    104     15     28     92    135    0.000   9
  Yoo              2015   Lung          Korea     Asian       HB               FIHP              Low                499    465       130   1094    487    472    98    1057   0.283   9
  De Martino       2016   RCC           Austria   Caucasian   HB               ES                Low                24     123       92    239     121    151    94    366    0.001   5
  Oztas            2016   Breast        Turkey    Caucasian   HB               PCR-RFLP          Low                40     52        15    107     26     62     20    108    0.115   9
  Xing             2016   Lung          China     Asian       HB               TaqMan            Low                210    161       47    418     264    123    23    410    0.092   8
  Lu               2016   Bladder       China     Asian       HB               PCR-RFLP          Low                58     95        48    201     80     88     32    200    0.349   8
  Carkic           2016   OSCC          Serbia    Caucasian   HB               PCR-RFLP          Low                38     45        7     90      15     73     12    100    0.000   6
  Xiao             2017   Lung          China     Asian       HB               TaqMan            Low                78     95        30    203     123    77     25    225    0.020   7
  Yuan             2017   HCC           China     Asian       HB               TaqMan            Low                85     127       19    231     94     115    31    240    0.650   7

HWE, Hardy-Weinberg equilibrium; OSCC, oral squamous cell carcinoma; RCC, renal cell carcinoma; SCCHN, squamous cell carcinoma of head and neck; HCC, hepatocellular carcinoma; ALL, acute lymphoblastic leukemia; PB, population based; HB, hospital based; PCR, polymerase chain reaction; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; FIHP, Fluorescence-labeled hybridization probes; ES, electrophoretic separation.

Meta-analysis results {#s2_2}
---------------------

We presented the detailed results of association between rs2736098 polymorphism and cancer risk in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}. Overall, we detected significant association between rs2736098 polymorphism and cancer risk among four genetic models (AA vs. GG: OR = 1.26, 95% CI = 1.09--1.47; AA vs. AG/GG: OR = 1.22, 95% CI = 1.09--1.36; AA/AG vs. GG: OR = 1.13, 95% CI = 1.02--1.24; A vs. G: OR = 1.11, 95% CI = 1.04--1.20). Stratification analysis by cancer type revealed that statistically significantly increased risk was found among lung cancer, bladder cancer, breast cancer, colorectal cancer, and other cancers, but not HCC and SCCHN. Further subgroup analysis by ethnicity, a significantly increased cancer risk was observed in Asians in all genetic models, but not Caucasians. As to the subgroup of control source, only hospital-based subgroup could contribute to increase risk of cancer. When stratified by quality score, significantly increased risk was observed in the score \> 9 group, but not ≤ 9 group. We also observed significantly increased risk in subgroup of those SNP of controls agreement with HWE in all genetic models tested (AA vs. GG: OR = 1.25, 95% CI = 1.08--1.43; AA vs. AG/GG: OR = 1.21, 95% CI = 1.08--1.36; AA/AG vs. GG: OR = 1.10, 95% CI = 1.01--1.19; A vs. G: OR = 1.10, 95% CI = 1.03--1.18), with the exception of the heterozygote comparison.

###### Meta-analysis of the association between *TERT* rs2736098 polymorphism and overall cancer risk

  Variables           No. of   Homozygous                        Heterozygous                      Recessive                         Dominant                          Allele              
  ------------------- -------- ------------------- ---------- -- ------------------- ---------- -- ------------------- ---------- -- ------------------- ---------- -- ------------------- ----------
  All ^a^             33       1.26 (1.09--1.47)   \< 0.001      1.09 (0.99--1.19)   \< 0.001      1.22 (1.09--1.36)   \< 0.001      1.13 (1.02--1.24)   \< 0.001      1.11 (1.04--1.20)   \< 0.001
  Cancer type                                                                                                                                                                              
  Lung                9        1.71 (1.51--1.94)   0.453         1.18 (1.05--1.34)   0.037         1.60 (1.42--1.80)   0.783         1.29 (1.14--1.46)   0.021         1.29 (1.18--1.41)   0.033
  Bladder             5        1.62 (1.27--2.08)   0.258         1.17 (0.93--1.45)   0.068         1.52 (1.24--1.85)   0.569         1.26 (1.01--1.57)   0.045         1.25 (1.08--1.45)   0.086
  HCC                 4        1.16 (0.87--1.54)   0.161         1.38 (0.97--1.95)   0.001         1.01 (0.78--1.30)   0.181         1.33 (0.98--1.79)   0.004         1.15 (0.97--1.36)   0.040
  Breast              3        0.64 (0.46--0.89)   0.235         0.87 (0.68--1.13)   0.194         0.71 (0.57--0.88)   0.361         0.80 (0.59--1.07)   0.117         0.82 (0.67--0.99)   0.107
  SCCHN               2        0.90 (0.70--1.16)   0.963         0.92 (0.81--1.05)   0.577         0.93 (0.73--1.20)   0.862         0.92 (0.81--1.04)   0.627         0.94 (0.85--1.03)   0.751
  Colorectal          2        0.48 (0.28--0.83)   0.611         0.54 (0.21--1.40)   0.047         0.73 (0.46--1.14)   0.630         0.59 (0.31--1.12)   0.097         0.72 (0.56--0.92)   0.371
  Others              8        1.26 (0.92--1.73)   \< 0.001      1.02 (0.80--1.30)   \< 0.001      1.23 (1.06--1.42)   0.121         1.06 (0.83--1.36)   \< 0.001      1.08 (0.91--1.27)   \< 0.001
  Ethnicity                                                                                                                                                                                
  Asians              23       1.43 (1.26--1.63)   \< 0.001      1.15 (1.05--1.25)   \< 0.001      1.33 (1.19--1.50)   0.001         1.21 (1.11--1.32)   \< 0.001      1.19 (1.12--1.27)   \< 0.001
  Caucasians          10       0.88 (0.61--1.25)   \< 0.001      0.90 (0.72--1.11)   \< 0.001      0.97 (0.80--1.17)   0.024         0.90 (0.72--1.11)   \< 0.001      0.93 (0.80--1.08)   \< 0.001
  Source of control                                                                                                                                                                        
  HB                  24       1.38 (1.16--1.65)   \< 0.001      1.16 (1.02--1.31)   \< 0.001      1.29 (1.15--1.50)   0.001         1.20 (1.06--1.37)   \< 0.001      1.17 (1.07--1.28)   \< 0.001
  PB                  9        1.03 (0.82--1.29)   \< 0.001      0.93 (0.87--0.99)   0.549         1.05 (0.85--1.31)   \< 0.001      0.96 (0.88--1.04)   0.164         0.99 (0.90--1.09)   0.002
  Quality score                                                                                                                                                                            
  \> 9                15       1.30 (1.10--1.54)   \< 0.001      1.02 (0.96--1.08)   0.530         1.29 (1.11--1.49)   0.001         1.07 (0.99--1.16)   0.021         1.10 (1.02--1.19)   \< 0.001
  ≤ 9                 18       1.23 (0.96--1.57)   \< 0.001      1.15 (0.96--1.39)   \< 0.001      1.15 (0.98--1.35)   \< 0.001      1.17 (0.97--1.41)   \< 0.001      1.12 (0.99--1.28)   \< 0.001
  HWE in controls                                                                                                                                                                          
  Yes                 27       1.25 (1.08--1.43)   \< 0.001      1.05 (0.98--1.12)   \< 0.001      1.21 (1.08--1.36)   \< 0.001      1.10 (1.01--1.19)   \< 0.001      1.10 (1.03--1.18)   \< 0.001
  No                  6        1.23 (0.62--2.44)   \< 0.001      1.08 (0.58--2.02)   \< 0.001      1.22 (0.87--1.71)   0.009         1.13 (0.62--2.04)   \< 0.001      1.12 (0.80--1.56)   \< 0.001

HWE, Hardy--Weinberg equilibrium; Het, heterogeneity; HCC, hepatocellular carcinoma; SCCHN, squamous cell carcinoma of head and neck; HB, hospital based; PB, population based.

![Forest plot of TERT rs2736098 polymorphism and overall cancer susceptibility (allele comparison model)\
The horizontal lines represent the study-specific ORs and 95% CIs, respectively. The diamond represents the pooled results of OR and 95% CI. The random effect model generates a constant from the homogeneity statistic Cochran\'s Q and using this and other study parameters a random effects variance component is generated. The inverse of the sampling variance plus this constant that represents the variability across the population effects is then used as the weight.](oncotarget-08-96433-g002){#F2}

Heterogeneity and sensitivity analysis {#s2_3}
--------------------------------------

We first conducted *Q* test and *I*^2^ statistics to test between-study heterogeneity. Heterogeneity was indicated among all five genetic models as *P* \< 0.001. Thus, the random-effect model was employed to generate wider CIs. As to the sensitivity analysis, the leaving each study out strategy showed that no substantial changes in ORs were observed after omitting each study (Figure [3](#F3){ref-type="fig"}). This reflects the stability and reliability of this meta-analysis.

![Sensitivity analysis of the association between *TERT* rs2736098 and cancer risk (allele comparison model)\
Each point represents the recalculated OR after omitting a separate study.](oncotarget-08-96433-g003){#F3}

Publication bias {#s2_4}
----------------

In Begg\'s funnel plots, we could not detect any obvious asymmetrical shape (Figure [4](#F4){ref-type="fig"}). Moreover, Egger\'s test result also revealed no evidence of publication bias among the studies (AA vs. GG: *P* = 0.92; AG vs. GG: *P* = 0.16; AA vs. AG + GG: *P* = 0.52; AA + AG vs. GG: *P* = 0.16; and A vs. G: *P* = 0.34).

![Funnel plot analysis to evaluate publication bias for TERT rs2736098 polymorphism (allele comparison model)\
Each point represents a separate study.](oncotarget-08-96433-g004){#F4}

DISCUSSION {#s3}
==========

In this meta-analysis, we attempted to settle down the debate about the role of *TERT* rs2736098 in cancer risk. The obtained results suggested that there exists a significant relationship between *TERT* rs2736098 and cancer risk. To the best of our knowledge, this updated meta-analysis involves the largest samples and the most convincing conclusions.

Numerous studies have investigated the role of *TERT* gene rs2746098 polymorphism in the contributions to cancer risk. To obtain a clear association between *TERT* rs2736098 and cancer risk, several meta-analyses have been performed. The first meta-analysis was conducted by Zhang et al. \[[@R14]\] in 2012, with 8 studies consisting of 8,070 cases and 10,239 controls. They claimed that no significant association was observed between *TERT* rs2736098 polymorphism and overall cancer risk. However, after stratified by ethnicity, a significantly increased risk of cancers was shown Among Asians. In another meta-analysis with 12 studies including 10044 cases and 12480 controls. Wu et al. \[[@R16]\] found that there was a borderline significant increased overall cancer risk conferred by rs2736098. In addition, such increased cancer risk was more obvious among lung cancer, bladder cancer, hospital-base design and Asians. The most recent published meta-analysis included 19 studies with 12520 cases and 14968 controls \[[@R18]\]. They found that GA/AA variant could contribute to increased risk of overall cancer. Their stratification analysis revealed that such association was more significant in Asians, lung cancer and hepatocellular carcinoma. It is obvious that conflict conclusions still exist, due to the relative small sample size included.

As several new studies have been updated since the latest meta-analysis, it is necessary for us to incorporate all the accessible studies to better elucidate the association between *TERT* rs2736098 polymorphism and cancer risk. In all, we found a significant relationship between *TERT* rs2736098 and cancer risk in the pooled analysis under all the five-genetic model, except for heterozygous model. Such findings were consistent with the results reported in the study of Wu et al. \[[@R16]\] and the latest meta-analysis \[[@R18]\]. Subgroup analysis by ethnicity suggested that individuals carrying *TERT* rs2736098 polymorphism from Asians but not among Europeans were more likely to exhibit an increased cancer risk, possibly because of the differences in genetic backgrounds among different populations. Our results suggested that genetic variants in *TERT* significantly increased the risk of lung cancer, bladder cancer, breast cancer, colorectal cancer and other cancer, but not HCC and SCCHN. These lines of evidence suggested that *TERT* rs2736098 polymorphism may have different effects in different cancer types. The possible reasons for discrepancies regarding cancer susceptibility may be ascribed to tumor specificity, differences in ethnicity, and variations in sample sizes included in each investigation.

To improve the quality of the current meta-analysis, we adopted some measurements below. First, our meta-analysis was the first to search literatures from both English and Chinese, with the aim to strengthen the reliability of our conclusions. Second, we adopted sensitivity analysis and publication bias assay, and the results indicated that the conclusions are robust and no publication bias was detected.

Yet, some limitations still exist and thus cautions are needed before interpreting the results obtained from the current meta-analysis. First, the number of included studies is far from enough to obtain a robust conclusion, especially for stratified analysis. Second, the validity of conclusion might be discount as significant between-study heterogeneity was observed in some comparisons. Third, we only calculated the crude ORs, but not the adjusted ORs, due to the lack of other important information like environmental factors, age, drinking status, and gene-environment interactions. Fourth, selection bias could not be avoided, as only the studies written in English or Chinese were extracted. Last, nearly all the eligible case-control studies included were conducted among Asians and Caucasians, other ethnicities such as Africans were not undertaken. Concerning genetic and geographical differences, additional studies are needed to further confirm such conclusion from other ethnicities, especially Africans.

To sum up, the current meta-analysis provides a powerful evidence that *TERT* rs2736098 polymorphism is associated with cancer risk, from the perspective of the formed case-control studies. However, it is still needed for us to continue providing more new evidence based on large sample size, multi-center investigation case-control studies.

MATERIALS AND METHODS {#s4}
=====================

Publication search {#s4_1}
------------------

A comprehensive literature search was first conducted in English electronic database PubMed and EMBASE using the combination of the following items: "polymorphism or single nucleotide polymorphism or SNP or variant" and "*TERT* or *hTERT* or rs2736098 or telomere reverse transcriptase", and "cancer or neoplasm or tumor or carcinoma". Then we further expanded the searching field to Chinese database China National Knowledge Infrastructure (CNKI) and Wanfang database using the same combination items in Chinese. The searching time was updated to August 2017. Moreover, we also included the eligible studies extracted from the references of retrieved articles. A single study would be treated as separate studies if two more ethnic subpopulations is included. Only the largest or the latest study was included if there exist two more articles with overlapping data. No language publication restrictions were set in this searching strategy. The designation and writing of this meta-analysis was under the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-analyses.

Eligibility criteria {#s4_2}
--------------------

In the current meta-analysis, only the studies met the following criteria were included: (1) studies published in English or Chinese; (2) unrelated case-control studies; (3) tested for the association of TERT rs2736098 polymorphism with cancer risk; (4) enough information to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Studies that failed to meet the above criteria were excluded in the final analysis.

Data extraction {#s4_3}
---------------

We arranged two authors (Tingyuan and Minjie) to screen the articles and extracted available data from all eligible studies, blindly. The data shown below were extracted: first author\'s surname, publication year, country, ethnicity, the source of controls, genotyping methods, quality score, and numbers of cases and controls with AA, AG and GG genotypes. Any discrepancy was resolved after full discussion.

Quality assessment {#s4_4}
------------------

To strengthen the robustness of our meta-analysis, a quality assessment was performed to all the included studies through adopting the quality assessment criteria ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). In brief, the quality scores range from 0 to 15. The studies with a score less than 9 were classified as low quality, while those more than 9 were classified as high quality.

Statistical methods {#s4_5}
-------------------

We first adopted goodness-of-fit χ^2^ test to assess whether the SNP in the control was departure from HWE. The strength of the association between *TERT* rs2736098 polymorphism and overall cancers risk was measured by calculating crude ORs and their 95% CIs using all five genetic models: homozygous model (AA vs. GG), heterozygous model (AG vs. GG), recessive model (AA vs. AG + GG), dominant model (AA + AG vs. GG) and allele comparison (A vs. G). Stratification analyses were also performed by ethnicity, and source of control, quality score, and HWE in controls. Between-study heterogeneity was analyzed by the Cochran\'s *Q* test and quantified by *I*^2^ statistics. When homogeneity existed, the fixed model (Mantel-Haenszel method) was used to calculate the summary ORs and 95% CIs; otherwise, the random-effects model (the DerSimonian and Laird method) was utilized. Sensitivity analysis was done by individually removing studies one by one and reanalyzing the pooled risk estimates. Publication bias was further assessed using Begg\'s funnel plot and Egger\'s linear regression, with that asymmetric plot and a *P value* \< 0.05 indicating the presence of publication bias. All statistical analysis was completed using STATA software (Stata Corporation, College Station, TX; version 11.0). All the statistics were two-sided with significant findings set at a *P value* of \< 0.05.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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